Rigel Pharmaceuticals Inc financial data

Symbol
RIGL on Nasdaq
Location
611 Gateway Boulevard, Suite 900, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 208 % +27.3%
Quick Ratio 9.55 % -15.2%
Debt-to-equity 670 %
Return On Equity 439 % +841%
Return On Assets 57 %
Operating Margin 39 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.9M shares +1.95%
Common Stock, Shares, Outstanding 17.7M shares +1.3%
Entity Public Float 143M USD -35.7%
Common Stock, Value, Issued 18K USD +5.88%
Weighted Average Number of Shares Outstanding, Basic 17.9M shares +1.92%
Weighted Average Number of Shares Outstanding, Diluted 18.2M shares +3.49%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 268M USD +106%
Costs and Expenses 163M USD +17.2%
Operating Income (Loss) 105M USD +13570%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 60M USD
Income Tax Expense (Benefit) 369K USD
Net Income (Loss) Attributable to Parent 97.8M USD
Earnings Per Share, Basic 5 USD/shares
Earnings Per Share, Diluted 5 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 53.4M USD +48.1%
Cash, Cash Equivalents, and Short-term Investments 108M USD +121%
Accounts Receivable, after Allowance for Credit Loss, Current 39.9M USD +38.1%
Inventory, Net 10.4M USD +29.3%
Other Assets, Current 5.44M USD
Assets, Current 175M USD +85.2%
Property, Plant and Equipment, Net 57K USD -50.4%
Operating Lease, Right-of-Use Asset 1.18M USD +110%
Other Assets, Noncurrent 4.18M USD -11.6%
Assets 207M USD +61%
Accounts Payable, Current 7.29M USD +18.9%
Employee-related Liabilities, Current 7.9M USD +23.9%
Contract with Customer, Liability, Current 1.36M USD 0%
Liabilities, Current 86.6M USD +47.7%
Operating Lease, Liability, Noncurrent 714K USD
Other Liabilities, Noncurrent 40M USD 0%
Liabilities 125M USD -21.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 6K USD
Retained Earnings (Accumulated Deficit) -1.32B USD +6.9%
Stockholders' Equity Attributable to Parent 81.9M USD
Liabilities and Equity 207M USD +61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -893K USD +82.2%
Net Cash Provided by (Used in) Financing Activities 484K USD
Net Cash Provided by (Used in) Investing Activities -10.6M USD -3471%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 17.7M shares +1.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 53.5M USD +48.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.65M USD -1.84%
Deferred Tax Assets, Valuation Allowance 329M USD -2.78%
Deferred Tax Assets, Gross 329M USD -2.78%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 97.8M USD
Lessee, Operating Lease, Liability, to be Paid 1.39M USD +106%
Property, Plant and Equipment, Gross 353K USD -81.1%
Operating Lease, Liability, Current 517K USD -19.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 409K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 692K USD +130%
Deferred Tax Assets, Operating Loss Carryforwards 223M USD -3.14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 8.78M USD +1.25%
Operating Lease, Payments 116K USD -84.4%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.3M USD +53.3%
Depreciation, Depletion and Amortization 604K USD +51%
Share-based Payment Arrangement, Expense 11.3M USD -1.79%
Interest Expense 7.74M USD +0.43%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%